Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of CDNF in patients with Parkinson's
disease, when dosed directly into the brain using an implanted investigational drug delivery
system (DDS). Safety and accuracy of the DDS is also being evaluated. One-third of the
patients will receive monthly infusions with placebo and two-third of the patients will
receive monthly infusions with either mid- or high-doses of CDNF for a period of 6 months.